APA (7th ed.) Citation

SA, H., LD, B., D, C., CT, H., FC, K., FP, S., . . . DJ, S. (2014). Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer. SpringerPlus, 3, 244. https://doi.org/10.1186/2193-1801-3-244

Chicago Style (17th ed.) Citation

SA, Hurvitz, Bosserman LD, Chan D, Hagenstad CT, Kass FC, Smith FP, Rodriguez GI, Childs BH, and Slamon DJ. "Cardiac Safety Results from a Phase II, Open-label, Multicenter, Pilot Study of Two Docetaxel-based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects with Node-positive or High-risk Node-negative Breast Cancer." SpringerPlus 3 (2014): 244. https://doi.org/10.1186/2193-1801-3-244.

MLA (9th ed.) Citation

SA, Hurvitz, et al. "Cardiac Safety Results from a Phase II, Open-label, Multicenter, Pilot Study of Two Docetaxel-based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects with Node-positive or High-risk Node-negative Breast Cancer." SpringerPlus, vol. 3, 2014, p. 244, https://doi.org/10.1186/2193-1801-3-244.